OR5D18 Inhibitors
OR5D18 inhibitors refer to a group of chemical compounds designed to inhibit the activity of the OR5D18 protein, a G-protein-coupled receptor (GPCR) that is part of the olfactory receptor family. Olfactory receptors are typically known for their role in detecting odorants, which activate signal transduction pathways in the olfactory system, primarily in the nose. However, olfactory receptors like OR5D18 have been found to have roles beyond their traditional sensory function. The OR5D18 receptor, like other GPCRs, undergoes conformational changes upon binding to ligands, triggering intracellular signaling cascades that regulate cellular responses. Inhibitors targeting OR5D18 are designed to block the receptor's interaction with its specific ligands, which may prevent or modulate these signaling pathways.
The design and study of OR5D18 inhibitors focus heavily on understanding the molecular structure and binding dynamics of this receptor. Since OR5D18, like other olfactory receptors, is embedded in the cellular membrane, inhibitors need to be lipophilic enough to interact within the membrane environment while also being selective enough to avoid off-target effects on other olfactory receptors or GPCRs. The specificity of these inhibitors is crucial in ensuring that they bind selectively to OR5D18's active site. Researchers often use computational modeling techniques to predict the binding affinity and molecular interactions of potential inhibitors. These compounds may undergo further biochemical testing to evaluate their potency and ability to modulate OR5D18's activity, providing valuable insights into the broader function of olfactory receptors within different biological systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A may downregulate OR5D18 by altering chromatin accessibility near the gene, making the transcriptional start site less available to RNA polymerase II. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine could decrease OR5D18 expression by causing DNA demethylation, potentially triggering a compensatory silencing mechanism in the olfactory receptor gene cluster. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D might inhibit OR5D18 transcription by binding to DNA sequences at the gene's promoter region, obstructing the advancement of RNA polymerase along the DNA template. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
Alpha-amanitin may decrease the synthesis of OR5D18 mRNA by directly inhibiting RNA polymerase II, leading to a reduction in the olfactory receptor's protein levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide could inhibit the overall expression of OR5D18 by halting the elongation phase of translation, thereby reducing the synthesis of the receptor protein. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may downregulate OR5D18 expression through the inhibition of the mTOR pathway, which can lead to a general decrease in cap-dependent translation, including that of OR5D18 mRNA. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $42.00 $185.00 $310.00 $650.00 | 6 | |
5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB) might inhibit the elongation phase of transcription of the OR5D18 gene, resulting in a decrease in the full-length mRNA transcripts available for translation. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Mithramycin A can bind to GC-rich sequences in the DNA, which could inhibit the binding of specific transcription factors to the OR5D18 promoter, leading to decreased expression. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine may reduce OR5D18 expression by intercalating into DNA and RNA, which could disrupt the transcription and/or stability of OR5D18 mRNA. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 could downregulate OR5D18 by competitively inhibiting BET bromodomain-containing proteins, which may be necessary for the transcription of OR5D18. | ||||||